Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04450173
Title Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Joseph Tuscano

follicular lymphoma


Ibrutinib + Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.